FGFR2 and cholangiocarcinoma: Notably, several next-generation FGFR inhibitors have shown preclinical activity and preliminary clinical activity in patients with cholangiocarcinoma harboring FGFR2 kinase domain mutations and urothelial cancer harboring FGFR3 kinase domain mutations following previous FGFR inhibitor treatment16,21,32,42–44.